Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)

NCT03855865 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business decision to stop the program.

Conditions

Depressive Disorder, Major

Interventions

DRUG: Rapastinel
DRUG: Vortioxetine
DRUG: Placebo

Sponsor

Naurex, Inc, an affiliate of Allergan plc